News

To combat rising maternal mortality, researchers at Saint Luke's Mid America Heart Institute and UMKC are leading a first of its kind study to create better care for moms with heart conditions during pregnancy.

While chemotherapy, radiation, and surgeries are common for most cancer treatments, immunotherapy is continuing to allow some patients to forgo these often harsh and invasive methods altogether.

A local man with heart failure who was told numerous times he only had months to live gets a second chance at life after treatment at Saint Luke's.

Dr. Adnan Chhatriwalla, interventional cardiologist at Saint Luke’s Mid America Heart Institute, talks about symptoms of heart valve disease, treatment, and keys to long-term heart health.

One patient's experience more than a decade ago was a pivotal moment for both Saint Luke’s Mid America Heart Institute and Saint Luke's Hospital Maternal-Fetal Medicine Program.

More than 10 years after his diagnosis, he’s helping other people with the same rare cancer to hold on to hope.

The four-year observational study will research U.S. pregnant people with cardiovascular disease to better understand and combat maternal mortality and morbidity.

In the past, many women born with a heart condition were told they would not be able to birth children safely.